

PORTUGAL

Recent and planned developments in pharmaceutical policies 2017

Special topic: e-health for medicines launched by public authorities or addressing them

D E V E L O P M E N T S	<p style="text-align: center;">CHANGES IN PRICING</p> <ul style="list-style-type: none"> • Annual price review: for non-generics (outpatient and inpatient) (01/2017) • External reference pricing: Spain, France and Italy (changed from Slovakia) are the reference countries in 2017 (01/2017) 	<p style="text-align: center;">CHANGES IN REIMBURSEMENT</p> <ul style="list-style-type: none"> • Medical devices: 100% reimbursement of medical devices for Ostomy patients with incontinence / urinary retention (04/2017) • Changes to the reference price system – Reference price is the average of the 5 lowest prices of the cluster, but cannot exceed the price of the most expensive generic – <i>not implemented yet</i>
	<p style="text-align: center;">OTHER CHANGES</p> <ul style="list-style-type: none"> • Dispensing fee – pharmacies' fee for the dispensing of the cheapest reimbursed medicines included in homogeneous groups (01/2017) • Agreement with Pharmaceutical Industry: addendum to the three-year agreement (2016-2018), setting the goals and principles for NHS charges, setting targets for increasing access to innovation and the use of generics, while maintaining the sustainability of NHS (01/2017). • Agreement with the Associations of Pharmacies: two-year agreement aims to strengthen the provision of public health services in conjunction with the NHS, such as the exchange of syringes or the dispensing of HIV / AIDS medicines at community pharmacies (01/2017). • Campaign for the rational use of medicines for the heartburn and indigestion (01/2017). • Newsletters on medicines - First infographics is dedicated to HIV / AIDS infection (01/2017). • Upgrading of SIATS (IT System for HTA Management): inclusion of the module 'notification on the market introduction of medicines' as well as the application for 'authorization for specific patient'. Current features include application for pricing and reimbursement, medicine shortages and cessation of marketing (03/2017). 	
S P E C I A L T O P I C	<p>E-HEALTH FOR MEDICINES</p>	
	<div style="display: flex; justify-content: space-around; align-items: center;">   </div> <p>Measure: Paperless Prescription - dematerialised e-prescription and e-dispensation</p> <p>Provided by: Shared Services of the Ministry of Health (SPMS,EPE)</p> <p>Aim: 100% paperless for 100% e-prescriptions, with stronger prescriber authentication safety; abolition of paper; no limits to the number or medicines in each prescription; lower costs; alternate ways to access the prescription in case of Treatment Guide Loss; possibility of partial dispensations (p.e. long term prescriptions); possibility of achieving medicines on more than one pharmacy based on the same prescription (p.e. stock breaks); added capabilities to fight fraud.</p> <p>Target group: patients, prescribers, community pharmacies</p>	<div style="display: flex; justify-content: space-between; align-items: center;">  </div> <p>Measure: App for mobile devices "Save on prescriptions" for access to the medicines prices, in order to facilitate the identification of the cheapest options</p> <p>Provided by: INFARMED</p> <p>Aim: helps to identify the cheapest medicine available for the active substance prescribed by the doctor. It also allows to view the product information leaflet, to check news and alerts on medicines and health products, to locate pharmacies in close proximity and to create a medication intake plan with an alert system. It also allows reading the barcodes of the packaging of the medicines, to immediately access the information.</p> <p>Target group: patients</p>
<div style="text-align: center;">  </div> <p>Measure: HEPC – Monitoring Registry for Hepatitis C</p> <p>Provided by: INFARMED</p> <p>Aim: Dematerialization of requests for access to medicines for the treatment of hepatitis C, with procedure carried out exclusively online. Monitoring performance after treatment, for reassessment of medicines for the treatment of hepatitis C. Alive since November 10, 2014</p> <p>Target group: patients, doctors</p>	<div style="text-align: center;">  </div> <p>Measure: Telepharmacy pilot</p> <p>Provided by: Unidade Local de Saúde do Litoral Alentejano (ULSLA)</p> <p>Aim: decentralization to primary health care units of the direct dispensing to the patient of medicines that are exclusively of the hospital pharmacy. At the time medicines are delivered to the patients, there's a teleconsultation between the patient accompanied by a nurse and the hospital professional, thus avoiding long distance travel.</p> <p>Target group: patients, doctors</p>	